Risk of Clostridium difficile diarrhoea in critically ill patients treated with erythromycin-based prokinetic therapy for feed intolerance.
OBJECTIVE
To determine the incidence of Clostridium difficile (CD) diarrhoea in feed-intolerant, critically ill patients who received erythromycin-based prokinetic therapy.


METHODS
Prospective observational study in a mixed intensive care unit.


METHODS
The development of diarrhoea (> 3 loose, liquid stool per day with an estimated total volume > or = 250ml/day) was assessed in 180 consecutive critically ill patients who received prokinetic therapy (erythromycin only, n = 53; metoclopramide, n 37; combination erythromycin/metoclopramide, n = 90) for feed intolerance. Stool microscopy, culture and CD toxin assay were performed in all patients who developed diarrhoea during and after prokinetic therapy. Diarrhoea was deemed to be related to CD infection if CD toxin was detected.


RESULTS
Demographics, antibiotic use and admission diagnosis were similar amongst the three patients groups. Diarrhoea developed in 72 (40%) patients, 9.9 +/- 0.8 days after commencement of therapy, none of whom was positive for CD toxin or bacterial infection. Parasitic infections were found in four aboriginal men from an area endemic for these infections. Diarrhoea was most prevalent in patients who received combination therapy (49%) and was more common than in those who received erythromycin alone (30%) and metoclopramide alone (32%). Diarrhoea was short-lasting with a mean duration of 3.6 +/- 1.2 days.


CONCLUSIONS
In critical illness, diarrhoea following the administration of erythromycin at prokinetic doses is not associated with CD but may be related to pro-motility effects of the agent. Prokinetic therapy should be stopped at the onset of diarrhoea and prophylactic use should be strictly avoided.
Nguyen
Nam Q
NQ
Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, North Terrace, 5000, Adelaide, Australia. namphoung28@hotmail.com
Ching
Katrina
K
Fraser
Robert J
RJ
Chapman
Marianne J
MJ
Holloway
Richard H
RH
D001315:Australia / Q000453:epidemiology; D016360:Clostridioides difficile; D016638:Critical Illness; D003967:Diarrhea / Q000453:epidemiology* / Q000382:microbiology; D004338:Drug Combinations; D004750:Enteral Nutrition / Q000009:adverse effects; D004761:Enterocolitis, Pseudomembranous / Q000139:chemically induced*; D004917:Erythromycin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D004338:Drug Combinations; D005765:Gastrointestinal Agents; D004917:Erythromycin
Eur J Gastroenterol Hepatol. 1995 Aug;7(8):797-802
7496872
Chest. 2001 Apr;119(4):1222-41
11296191
J Infect Dis. 1994 Jul;170(1):227-30
8014506
J Crit Care. 1999 Jun;14(2):73-7
10382787
J Hosp Infect. 2003 Jul;54(3):243-5
12855243
Nurs Res. 1990 May-Jun;39(3):148-52
2111543
Pharmacotherapy. 2000 Dec;20(12):1486-98
11130221
Crit Care Clin. 1995 Apr;11(2):465-77
7788541
Intensive Care Med. 2005 Jul;31(7):949-54
15940460
Crit Care Med. 1994 Mar;22(3):441-7
8124995
Chest. 2002 Jan;121(1):301-2
11796472
Am J Med. 1999 Oct;107(4):356-62
10527038
Anaesth Intensive Care. 2001 Dec;29(6):619-22
11771607
Gut. 2003 Dec;52 Suppl 7:vii1-vii12
14612488
Crit Care Med. 1983 Jan;11(1):7-9
6848311
Crit Care Med. 2007 Feb;35(2):483-9
17205032
Crit Care. 2006 Feb;10(1):112
16420656
JPEN J Parenter Enteral Nutr. 1992 Mar-Apr;16(2):99-105
1556825